Biobank

The Prostate Biobank at Oslo University Hospital (Regional Ethical Committee for medical and healthcare research ethics Ref. 28144) is annually collecting formalin-fixed paraffin-embedded tissue samples from approximately 250 patients undergoing radical prostatectomy.

Sample types collected since 2006
  FF tissue Blood Serum Plasma Germline DNA
Total 2794 1171 1290 1290 1280

Blood samples were routinely collected in the period 2006-2013. Matched serum and FF samples are available from more than 790 patients.

Number of patients (serum samples) linked to PSA subgroups

PSA

PSA <10

10< PSA >20

PSA >20

Total

n=

751

370

86

1207

Number of patients (serum samples) linked to pathological subgroups

Grade Group biopsy

1

2

3

4

5

Total

n=

508

413

140

129

17

1207

Grade Group RP

1

2

3

4

5

Total

n=

381

476

219

94

31

1207

pT-stage pT1-pT2   pT3a pT3b - pT4   Total
n= 714   384 105   1207

Initially, 1-2 FF tissue cores were sampled from each prostatectomy specimen. In 2011, the Prostate Biobank implemented the “Multiple core protocol” allowing to address prostate cancer heterogeneity. 5-7 cores are collected per prostatectomy specimen. More than 95% of the samples are snap frozen within 15 minutes after arrival to the Department of Pathology. The average RNA Integrity Number (RIN) value based on Allprep DNA/RNA/miRNA Universal kit (Qiagen, Venlo, Netherlands) RNA extraction of 207 cores was 9.7 #.

Serum, plasma, and fresh frozen tissue as well as DNA are stored in 2D labeled tubes at minus 80 degrees Celsius in freezers with automatic, digital temperature logging. All samples are registered in the eBiobank system at Oslo University Hospital (OUS) and the clinical data in MedInsight.

The Research Biobank for Cancer has been responsible for the collection of biological samples from prostate cancer patients treated at OUS since fall 2019. Before that, biological samples were collected by The Prostate Biobank.

 

Strømme et al., Cancer Gene Therapy 2022